ReviewJournal of clinical medicine2021
Clinical Practice of Photodynamic Therapy Using Talaporfin Sodium for Esophageal Cancer.
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase III Randomized Controlled Study of the Effect of Different Light Doses on Adverse Outcomes of Swallowing in Esophageal Cancer
A Phase III, Randomized, Controlled Study of Endoscopic Submucosal Dissection Versus Photodynamic Therapy for Early Esophageal Cancer
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial.Cancer science · 2026Article
- Efficacy and safety of photodynamic therapy using an ultra-thin endoscope for local failure with esophageal stenosis after chemoradiotherapy for esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Review
- [Hollow copper sulfide nanocomposites combined with photothermal and photodynamic therapy inhibits malignant behaviors of esophageal cancer cells].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Natural Chlorin eACS omega · 2026Article
- Article
- cGAS-STING Pathway Activation Enhances Antitumor Effect of Talaporfin Photodynamic Therapy Through ROS Production.Cancer science · 2025Article
- Preclinical evaluation of sodium copper chlorophyllin: safety, pharmacokinetics, and therapeutic potential in breast cancer chemotherapy and cyclophosphamide-induced bladder toxicity.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- Ce6-GFFY is a novel photosensitizer for colorectal cancer therapy.Genes & diseases · 2025Article
- Photodynamic therapy and tumor-treating fields therapy for newly diagnosed glioblastoma.Frontiers in oncology · 2025Article
- Photoimmunotherapy for cancer treatment based on organic small molecules: Recent strategies and future directions.Translational oncology · 2024Review
- Evaluation of a Novel Lateral Emitting Laser Fiber for Near-Infrared Photoimmunotherapy.Cancers · 2024Article
- Article
- Near-Infrared Fluorescence Imaging Sensor with Laser Diffuser for Visualizing Photoimmunotherapy Effects under Endoscopy.Sensors (Basel, Switzerland) · 2024Article
- Enhancement of cytotoxic effects with ALA-PDT on treatment of radioresistant cancer cells.Journal of clinical biochemistry and nutrition · 2024Article
- Methylene Blue-Mediated Photodynamic Therapy in Combination With Doxorubicin: A Novel Approach in the Treatment of HT-29 Colon Cancer Cells.Journal of lasers in medical sciences · 2024Article
- Vascular-targeted photodynamic therapy with glucose-conjugated chlorin e6 for dogs with spontaneously occurring tumours.Veterinary medicine and science · 2023Article
- Photodynamic Therapy: From the Basics to the Current Progress ofMolecules (Basel, Switzerland) · 2023Review
- In Vitro Comparative Study of Near-Infrared Photoimmunotherapy and Photodynamic Therapy.Cancers · 2023Article
- Endoscopic image-guided laser treatment system based on fiber bundle laser steering.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) using a conventional photosensitizer was approved for esophageal cancer in the early 1990s; however, it was replaced by other conventional treatment modalities in clinical practice because of the high frequency of cutaneous phototoxicity and esophageal stricture after the procedure. The second-generation photosensitizer, talaporfin sodium, which features more rapid clearance from the body, was developed to reduce skin phototoxicity, and talaporfin sodium can be excited at longer-wavelength lights comparing with a conventional photosensitizer. Endoscopic PDT using talaporfin sodium was initially developed for the curative treatment of central-type early lung cancer in Japan, and was approved in the early 2000s. After preclinical experiments, PDT using talaporfin sodium was investigated for patients with local failure after chemoradiotherapy, which was the most serious unmet need in the practice of esophageal cancer. According to the favorable results of a multi-institutional clinical trial, PDT using talaporfin sodium was approved as an endoscopic salvage treatment for patients with local failure after chemoradiotherapy for esophageal cancer. While PDT using talaporfin sodium is gradually spreading in clinical practice, further evaluation at the point of clinical benefit is necessary to determine the importance of PDT in the treatment of esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.